Please login to the form below

Not currently logged in
Email:
Password:

Wilson disease

This page shows the latest Wilson disease news and features for those working in and with pharma, biotech and healthcare.

AstraZeneca signs for-profit agreements for its COVID-19 vaccine

AstraZeneca signs for-profit agreements for its COVID-19 vaccine

its COVID-19 vaccine, citing its shift from a pandemic to an endemic disease. ... The results include Lynparza in prostate cancer, Imfinzi plus tremelimumab in liver cancer and biliary tract cancer, PT027 in asthma, ALXN1840 in Wilson disease, and

Latest news

  • AZ’s new rare disease unit wins in Wilson disease AZ’s new rare disease unit wins in Wilson disease

    Alexion purchase looks increasingly ‘copper-bottomed’ as AstraZeneca prepares to submit data for ALXN1840 in Wilson disease. ... Wilson disease is a rare, progressive genetic condition in which the body’s pathway for removing excess copper is

  • Pfizer goes big on gene therapy with $500m facility spend Pfizer goes big on gene therapy with $500m facility spend

    It also took a 15% stake in  Vivet Therapeutics and its lead programme for Wilson disease, a devastating rare, chronic and potentially life-threatening liver disorder.

  • Pfizer buys dwarfism drug company Therachon for $810m Pfizer buys dwarfism drug company Therachon for $810m

    Pfizer has been steadily adding to its rare disease assets via a series of takeovers and alliances to complement its own R&D in this area. ... TA-46 will add to other pipeline candidates including Sangamo-partnered haemophilia A gene therapy SB-525,

  • Pfizer hedges bets on gene therapy deal Pfizer hedges bets on gene therapy deal

    Vivet Therapeutics’ lead candidate is VTX-801, a gene therapy for Wilson disease, a devastating rare, chronic, and potentially life-threatening liver disorder. ... Pfizer will work closely with Vivet to help it develop its expertise in liver-directed

  • Alexion adds to pipeline with $1.2bn Syntimmune buy Alexion adds to pipeline with $1.2bn Syntimmune buy

    Alexion has agreed a $1.2bn takeover of US biotech Syntimmune that will add another clinical-stage rare disease drug to its R&D pipeline. ... $855m, adding orally-active copper binder WTX-101 in phase 3 testing for genetic disorder Wilson’s disease.

More from news
Approximately 1 fully matching, plus 8 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
foxandcat.online

We help communications teams to thrive under pressure. Here at fox&cat, we help all kinds of teams to fight all...

Latest intelligence

Our Top 5 Pharma Picks From Cannes Lions
Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
The Evolving Role of the Sales Rep
The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
Measure your omnichannel maturity with our new tool
Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....